SCHEMBL17456958

SCHEMBL17456958

CC(=O)Nc1ccccc1OCC(=O)c1cc(C)n(Cc2cccs2)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 11/20 1.00
▸ ALDH1A1 P00352 9/20 1.00
▸ LMNA P02545 9/20 1.00
▸ TSHR P16473 8/20 1.00
▸ MAPT P10636 6/20 1.00
▸ HTT P42858 4/20 1.00
▸ NR2F2 P24468 2/20 1.00
▸ HSP90AA1 P07900 1/20 1.00
▸ MAPK1 P28482 4/20 0.62
▸ NOD2 Q9HC29 1/20 0.62
▸ POLB P06746 4/20 0.59
▸ L3MBTL1 Q9Y468 3/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ NCOA3 Q9Y6Q9 1/20 0.59
▸ RAB9A P51151 12/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ KLF5 Q13887 1/20 0.59
▸ NOD1 Q9Y239 1/20 0.59
▸ TP53 P04637 7/20 0.58
▸ MEN1 O00255 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20741111 0.76 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL20423503 0.74 RAB9A (1.00) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL4114205 0.73 RAB9A (0.81) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL15987441 0.73 RAB9A (0.66) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL24834367 0.69 RAB9A (0.59) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL21003145 0.68 LMNA (0.51) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL10694274 0.67 RAB9A (0.53) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL7360102 0.66 BRD4 (0.69) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL6212540 0.65 BRD4 (0.63) SMN1; SMN2ALDH1A1LMNATSHRMAPT
SCHEMBL24257133 0.65 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1LMNATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220249436-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC (US) 2022-08-11 — — US disclosed
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 — — US disclosed
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans KCL THERAPEUTICS, INC. (US) 2022-05-10 — — US disclosed
US-11241427-B2 Small molecule modulators of NR2F6 activity KCL THERAPEUTICS, INC. (US) 2022-02-08 — — US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 — — US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 — — US disclosed
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals Zander Therapeutics, Inc. 2019-02-21 — — US disclosed
US-20180346456-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY SYBLEU INC. 2018-12-06 — — US disclosed
US-20180346455-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS SYBLEU INC. 2018-12-06 — — US disclosed
US-10088485-B2 Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand REGEN BIOPHARMA (US) 2018-10-02 — — US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 — — US disclosed
US-20160025746-A1 METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND KCL THERAPEUTICS, INC 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 SMN1; SMN2 2344/4885ALDH1A1 2069/4885LMNA 4829/4885
US-20180346455-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 SMN1; SMN2 2285/4885ALDH1A1 1783/4885LMNA 4829/4885
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 SMN1; SMN2 2285/4885ALDH1A1 1783/4885LMNA 4829/4885
US-11241427-B2 Small molecule modulators of NR2F6 activity NR2F2, NR2E3, NR2C2 SMN1; SMN2 2494/4885ALDH1A1 3037/4885LMNA 4730/4885
US-20220249436-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 SMN1; SMN2 2344/4885ALDH1A1 2069/4885LMNA 4829/4885
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals NR4A2, NR2C2, NR0B2 SMN1; SMN2 2285/4885ALDH1A1 1783/4885LMNA 4829/4885
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans NR4A2, NR2C2, NR0B2 SMN1; SMN2 2344/4885ALDH1A1 2069/4885LMNA 4829/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 SMN1; SMN2 2982/4885ALDH1A1 1909/4885LMNA 4840/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 SMN1; SMN2 2285/4885ALDH1A1 1783/4885LMNA 4829/4885
US-20180346456-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY NR4A2, NR2C2, NR2F2 SMN1; SMN2 2982/4885ALDH1A1 1909/4885LMNA 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback